TW202122111A - 用於藥物溶解度控制之氣相塗層 - Google Patents
用於藥物溶解度控制之氣相塗層 Download PDFInfo
- Publication number
- TW202122111A TW202122111A TW109129309A TW109129309A TW202122111A TW 202122111 A TW202122111 A TW 202122111A TW 109129309 A TW109129309 A TW 109129309A TW 109129309 A TW109129309 A TW 109129309A TW 202122111 A TW202122111 A TW 202122111A
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- particles
- less
- Prior art date
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 49
- 239000012808 vapor phase Substances 0.000 title 1
- 239000011248 coating agent Substances 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 239000002245 particle Substances 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims abstract description 19
- 239000011247 coating layer Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 21
- -1 poly(acrylate) Polymers 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 12
- 238000000231 atomic layer deposition Methods 0.000 claims description 9
- 238000005229 chemical vapour deposition Methods 0.000 claims description 8
- 229910044991 metal oxide Inorganic materials 0.000 claims description 8
- 150000004706 metal oxides Chemical class 0.000 claims description 8
- 238000000151 deposition Methods 0.000 claims description 7
- 230000008021 deposition Effects 0.000 claims description 7
- 239000010410 layer Substances 0.000 claims description 5
- 239000002052 molecular layer Substances 0.000 claims description 5
- 239000004952 Polyamide Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 238000009718 spray deposition Methods 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 206010034972 Photosensitivity reaction Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 229940124636 opioid drug Drugs 0.000 claims 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical group O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 1
- 230000036211 photosensitivity Effects 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 239000002841 Lewis acid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000007517 lewis acids Chemical class 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 239000002879 Lewis base Substances 0.000 description 3
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 150000007527 lewis bases Chemical class 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- OVISMSJCKCDOPU-UHFFFAOYSA-N 1,6-dichlorohexane Chemical compound ClCCCCCCCl OVISMSJCKCDOPU-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- UWCPYKQBIPYOLX-UHFFFAOYSA-N benzene-1,3,5-tricarbonyl chloride Chemical compound ClC(=O)C1=CC(C(Cl)=O)=CC(C(Cl)=O)=C1 UWCPYKQBIPYOLX-UHFFFAOYSA-N 0.000 description 1
- IRXBNHGNHKNOJI-UHFFFAOYSA-N butanedioyl dichloride Chemical compound ClC(=O)CCC(Cl)=O IRXBNHGNHKNOJI-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000007156 chain growth polymerization reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YVOFTMXWTWHRBH-UHFFFAOYSA-N pentanedioyl dichloride Chemical compound ClC(=O)CCCC(Cl)=O YVOFTMXWTWHRBH-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920002246 poly[2-(dimethylamino)ethyl methacrylate] polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/006—Coating of the granules without description of the process or the device by which the granules are obtained
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/60—Deposition of organic layers from vapour phase
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C16/00—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes
- C23C16/22—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the deposition of inorganic material, other than metallic material
- C23C16/30—Deposition of compounds, mixtures or solid solutions, e.g. borides, carbides, nitrides
- C23C16/40—Oxides
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C16/00—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes
- C23C16/44—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating
- C23C16/4417—Methods specially adapted for coating powder
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C16/00—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes
- C23C16/44—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating
- C23C16/455—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into reaction chamber or for modifying gas flows in reaction chamber
- C23C16/45523—Pulsed gas flow or change of composition over time
- C23C16/45525—Atomic layer deposition [ALD]
- C23C16/45555—Atomic layer deposition [ALD] applied in non-semiconductor technology
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D2258/00—Small objects (e.g. screws)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Mechanical Engineering (AREA)
- Metallurgy (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一種藥物組合物包括具有藥物活性成分、醫藥上可接受的賦形劑或兩者的顆粒。該等顆粒用包含醫藥上可接受的塗層材料的塗佈層包封。塗佈層小於200奈米厚。
Description
本揭示案涉及經塗佈的藥劑組合物及製備經塗佈的藥劑組合物的方法。
醫藥行業非常感興趣的是開發具有活性藥物成分（API）的改進製劑。製劑可影響API的穩定性和生物利用度以及其他特性。製劑亦可影響藥劑產品（DP）製造的各個方面，例如製造製程的簡便性和安全性。
已經開發了用於包封或塗佈API和DP兩者的多種技術，例如聚合物網狀塗層、鍋塗層、霧化塗層、流化床反應器塗層及原子層沉積塗層。
一種藥物組合物包括具有藥物活性成分、醫藥上可接受的賦形劑或兩者的顆粒。該等顆粒用包含醫藥上可接受的塗層材料的塗佈層包封。塗佈層小於200奈米厚。
在另一態樣中，一種對具有藥物活性成分的顆粒進行塗佈的方法包括使用原子層沉積、分子層沉積、化學氣相沉積、引發的化學氣相沉積或氣溶膠輔助噴霧沉積製程來施加一層醫藥上可接受的塗層材料。
提供了一種用於使用有機聚合物、無機金屬氧化物或兩者的薄的、保形的、均勻的、緻密的塗層來對藥物粉末進行塗佈的方法。此類塗層可表現出獨特的熱和/或pH響應的溶解特性。
厚的藥物塗層可以賦予所需的功能特性，諸如在指定溫度或pH範圍下的溶解度控制。然而，它們的厚度引入了重大的新問題，諸如藥代動力學變化或最終製劑中API含量的降低。
施加用於溶解度改變的塗層的現有方法要求包括大量塗層材料，以確保完全覆蓋所有顆粒，而不管該等顆粒的大小或形狀如何。由於該塗層的過重負載，塗層可能負面地影響藥物的藥理活性。本發明的塗層提供了低厚度（＜100 nm）的緻密、保形、無缺陷的膜來減輕此等問題。
該技術賦能薄、均勻、保形和緻密的塗層，而不管粒徑如何。此等高度精確的塗層可以最小化提供有效溶解度控制所需的塗層過度負載，從而最小化溶解度控制製劑影響藥理效能的風險。另外，可以製備有機-無機混合塗層結構，此可賦能新的溶解度控制和刺激響應模式。
該技術意欲生產用於製劑的藥物塗層，該等藥物塗層在最小化對體內藥理效能的影響的同時具有改善的體外溶解度。此可以使用薄的（＜100 nm）、保形的有機和無機塗層的組合來實現，該等塗層顯示出獨特的刺激響應溶解度特性。無機塗層可以由金屬氧化物（諸如Al2
O3
或TiO2
）組成。有機塗層可以由縮合聚合物（諸如聚酯或聚醯胺）或鏈增長聚合物組成，該等聚合物是由丙烯酸和甲基丙烯酸、丙烯醯胺、苯乙烯的酯或氨基酯及前述聚合物的共聚物合成的。塗層的獨特之處在於即使在具有高粒徑多分散性、表面粗糙度或深寬比的顆粒上，此等塗層也具有超薄（＜100 nm）、均勻和保形的結構。
在製程中經由原子層沉積（ALD）或化學氣相沉積（CVD）中的一者或多者來塗佈金屬氧化物材料。經由分子層沉積（MLD）、引發（熱絲）化學氣相沉積（iCVD）或氣溶膠輔助噴霧沉積製程（AA-CVD）中的一者或多者來塗層聚合物。該等技術共享塗層均勻性高、與粒徑無關、具有良好的保形覆蓋性和相對缺乏針孔缺陷的獨特益處，並且適用於其他地方所述的一般反應器結構。在沉積期間（藉由旋轉、氣體流動或振動）攪動要塗佈的顆粒，以確保高生產量和良好的均勻性。
藉由交替投加前驅物（諸如三甲基鋁（TMA）或TiCl4）和氧化劑（諸如水蒸氣或臭氧），在大約室溫至300℃的溫度下進行金屬氧化物的ALD沉積。藉由該方法製得的金屬氧化物的優異化學惰性和物理強度使得該等金屬氧化物成為用於溶解度控制的新候選者。它們亦顯示出依賴於pH的溶解度性質。在塗覆製程中，將前驅物以靜態模式或流通模式投加到反應器中。在靜態模式中，將金屬前驅物脈衝進入密閉的反應器中，並使金屬前驅物在反應器中停留，直到金屬前驅物藉由與表面反應而被消耗掉。隨後泵出反應副產物，並再次脈衝化反應物，直到粉末上的所有反應位點都已被佔據。隨後藉由惰性氣體流清除反應器中的殘餘反應物。隨後用氧化劑重複該循環。在流通模式中，將金屬前驅物的流速設定為使得在不關閉反應器排氣的情況下，金屬前驅物在反應器中被完全或幾乎完全消耗。監測排氣以識別反應終點，在此時用惰性氣體清除反應器，並用氧化劑重複該過程。在流通模式或靜態模式中，重複該循環，直到實現所需的膜厚為止。
可以經由分子層沉積（MLD）或引發的（熱絲）化學氣相沉積（iCVD）以類似的方式沉積有機聚合物層。MLD是一種類似於用於上述ALD的製程的替代製程，並且可用於沉積縮聚物，諸如聚醯胺和聚酯，該等縮聚物可以是支鏈的或交聯的。pH響應性聚酯或聚醯胺由於它們在不同環境中差異地控制溶解度的能力而特別有用。在MLD製程中，藉由投加交替的物理吸附或化學吸附的單層來對顆粒進行塗佈，該等單層由一對或多對互補的多官能路易斯酸和鹼組成。路易斯鹼可以由多官能醇（諸如二甘醇）或胺（諸如乙二胺）組成。路易斯酸可以由多官能的醯氯（諸如琥珀醯氯、戊二醯氯或己二醯氯）組成。三官能路易斯酸或鹼，諸如均苯三甲醯氯可用於引入支化或交聯。有機-無機混合材料亦可以使用金屬-有機前驅物（諸如TMA）作為路易斯酸來製備。如上面針對ALD所規定的，該等交替的層可以以靜態或流過模式投加。
ICVD製程可用於沉積鏈增長聚合物，諸如聚(丙烯酸酯)、聚(甲基丙烯酸酯)和聚(苯乙烯)及前述聚合物的共聚物。在該等材料中，丙烯酸和甲基丙烯酸的氨基酯（諸如pDMAEMA和pEMAEMA）特別受關注，因為它們的溶解度轉變強烈依賴於pH值。另外，水凝膠材料（諸如交聯的聚丙烯醯胺）由於其可溶脹性而亦顯示出對溶解度的顯著影響。在iCVD製程中，一種或多種選自乙烯基、丙烯酸酯、甲基丙烯酸酯、丙烯醯胺、甲基丙烯醯胺或苯乙烯化學物的子集的單體前驅體經由能夠遞送1-100 g/min的單體蒸氣的蒸氣遞送系統（亦即，起泡器或直接液體注入）流入反應器。共聚物亦可以藉由共注射多種不同單體來製備。相對飽和比和反應速率將決定沉積膜的組成。第二注射器提供熱引發劑（諸如有機過氧化物）的遞送。引發劑在進入反應器之前流經加熱的元件。該加熱的元件使引發劑在不與單體蒸氣相互作用的情況下裂解形成兩種過氧自由基。隨後該等自由基誘發物理吸附在待塗佈顆粒的表面上的單體物質的鏈增長聚合。
該等製程均導致緻密、保形、高度均勻的膜，該等膜無法藉由當今的現有藥物塗佈製程生產。該等精確塗佈由於刺激或熱響應而可實現良好的溶解度控制，同時由於塗層的極薄性而使塗層對藥理特性的影響最小化。此外，它們可以藉由以下方式來最小化賦形劑負載：在較薄的塗層中實現相同的效能，從而以較小的劑型因素實現增加的藥物劑量。最後，該等製程可以組合使用，以創建具有獨特的環境依賴性溶解度控制的層壓結構，從而允許在最小化塗層對體內效能的影響的同時調整藥物溶解度。
無
無
國內寄存資訊(請依寄存機構、日期、號碼順序註記)
無
國外寄存資訊(請依寄存國家、機構、日期、號碼順序註記)
無
Claims (23)
- 一種藥物組合物，包含顆粒，該等顆粒包含一藥物活性成分、一醫藥上可接受的賦形劑或兩者，其中該等顆粒被包含一醫藥上可接受的塗層材料的一塗佈層包封，其中該塗佈層為小於200奈米厚。
- 如請求項1所述之藥物組合物，其中該塗佈層為小於100 nm厚。
- 如請求項1所述之藥物組合物，其中該塗佈層為小於50 nm厚。
- 如請求項1所述之藥物組合物，其中該塗佈層為小於10 nm厚。
- 如請求項1所述之藥物組合物，其中該塗佈層為小於1 nm厚。
- 如請求項1所述之藥物組合物，其中該塗佈層包含兩種或更多種醫藥上可接受的塗層材料。
- 如請求項1所述之藥物組合物，其中該塗佈層包括包含一第一醫藥上可接受的塗層材料的一第一子層和包含一第二醫藥上可接受的塗層材料的一第二子層。
- 如請求項1所述之藥物組合物，其中基於一體積平均值，該等顆粒具有小於10微米的一中值粒徑。
- 如請求項1所述之藥物組合物，其中基於一體積平均值，該等顆粒具有小於1微米的一中值粒徑。
- 如請求項1所述之藥物組合物，其中基於一體積平均值，該等顆粒具有小於100奈米的一中值粒徑。
- 如請求項1所述之藥物組合物，其中該醫藥上可接受的塗層材料包含一金屬氧化物。
- 如請求項11所述之藥物組合物，其中該金屬氧化物是氧化鋁或二氧化鈦。
- 如請求項1所述之藥物組合物，其中該醫藥上可接受的塗層材料包含一聚醯胺或一聚酯。
- 如請求項1所述之藥物組合物，其中該醫藥上可接受的塗層材料包含諸如一聚(丙烯酸酯)、一聚(甲基丙烯酸酯)、一聚(苯乙烯)及前述材料的共聚物。
- 如請求項1所述之藥物組合物，其中該等顆粒包含藥物活性成分和一種或多種醫藥上可接受的賦形劑。
- 一種單位劑型，該單位劑型包含如請求項1所述之的藥物組合物。
- 如請求項16所述之單位劑型，其中該劑型是一錠劑或膠囊劑。
- 如請求項1所述之藥物組合物，其中該藥物活性成分不是一類鴉片藥物。
- 如請求項1所述之藥物組合物，其中該塗佈層改變以下項中的一者或多者：跟隨性、穩定性和光敏性。
- 如請求項1所述之藥物組合物，其中該塗佈層藉由原子層沉積或分子層沉積來施加。
- 一種對包含藥物活性成分的顆粒進行塗佈的方法，包括以下步驟：使用原子層沉積、分子層沉積、化學氣相沉積、引發的化學氣相沉積或氣溶膠輔助噴霧沉積製程來施加一醫藥上可接受的塗層材料的一層。
- 如請求項21所述之方法，包括以下步驟：施加包含一第一醫藥上可接受的塗層材料的一第一子層和包含一第二醫藥上可接受的塗層材料的一第二子層。
- 如請求項21所述之方法，其中該施加在低於50℃的溫度下進行。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962892475P | 2019-08-27 | 2019-08-27 | |
| US62/892,475 | 2019-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202122111A true TW202122111A (zh) | 2021-06-16 |
Family
ID=74683348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109129309A TW202122111A (zh) | 2019-08-27 | 2020-08-27 | 用於藥物溶解度控制之氣相塗層 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220296530A1 (zh) |
| EP (1) | EP4021421A4 (zh) |
| JP (2) | JP2022545279A (zh) |
| KR (1) | KR20220051385A (zh) |
| CN (1) | CN114423415A (zh) |
| TW (1) | TW202122111A (zh) |
| WO (1) | WO2021041675A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI126168B (en) | 2012-09-18 | 2016-07-29 | Novaldmedical Ltd Oy | A method for coating pharmaceutical substrates |
| BR112018017173A2 (pt) | 2016-02-23 | 2019-01-02 | Univ Colorado Regents | composições e métodos para a produção e uso de formulações imunogênicas termoestáveis com compatibilidade aumentada de uso como vacinas contra um ou mais patógenos |
| WO2019143744A1 (en) | 2018-01-16 | 2019-07-25 | Applied Materials, Inc. | Metal oxide encapsulated drug compositions and methods of preparing the same |
| CN118215470A (zh) | 2021-09-30 | 2024-06-18 | 应用材料公司 | 用于制药应用的低温氧化硅涂层 |
| WO2024226509A2 (en) * | 2023-04-24 | 2024-10-31 | The Regents Of The University Of California | Using polypeptoids for deposition and area-selective deposition of metal oxides |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003273000A1 (en) * | 2002-10-16 | 2004-05-04 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| JP4706785B2 (ja) * | 2008-09-30 | 2011-06-22 | アステラス製薬株式会社 | 経口投与用粒子状医薬組成物 |
| US9795576B2 (en) * | 2010-09-27 | 2017-10-24 | Basf Se | Protective coatings for acidic active ingredients |
| AU2012222650A1 (en) * | 2011-03-03 | 2013-10-17 | Merck Patent Gmbh | Coated solid pharmaceutical preparation |
| FI126168B (en) * | 2012-09-18 | 2016-07-29 | Novaldmedical Ltd Oy | A method for coating pharmaceutical substrates |
| LT3003286T (lt) * | 2013-05-24 | 2022-08-10 | Nanexa Ab | Kietųjų nanodalelių su neorganine danga gamybos būdas ir jų naudojimas |
| EP3209287A4 (en) * | 2014-10-20 | 2018-06-13 | RX Analytic Inc. | A drug-containing micro particle |
| US10373820B2 (en) * | 2016-06-01 | 2019-08-06 | Asm Ip Holding B.V. | Deposition of organic films |
| WO2019143744A1 (en) * | 2018-01-16 | 2019-07-25 | Applied Materials, Inc. | Metal oxide encapsulated drug compositions and methods of preparing the same |
-
2020
- 2020-08-27 EP EP20856082.1A patent/EP4021421A4/en not_active Withdrawn
- 2020-08-27 TW TW109129309A patent/TW202122111A/zh unknown
- 2020-08-27 WO PCT/US2020/048198 patent/WO2021041675A1/en not_active Ceased
- 2020-08-27 KR KR1020227009945A patent/KR20220051385A/ko not_active Ceased
- 2020-08-27 JP JP2022512333A patent/JP2022545279A/ja active Pending
- 2020-08-27 CN CN202080066007.7A patent/CN114423415A/zh active Pending
- 2020-08-27 US US17/636,293 patent/US20220296530A1/en active Pending
-
2024
- 2024-02-13 JP JP2024019264A patent/JP2024073417A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4021421A4 (en) | 2023-05-10 |
| US20220296530A1 (en) | 2022-09-22 |
| CN114423415A (zh) | 2022-04-29 |
| JP2024073417A (ja) | 2024-05-29 |
| WO2021041675A1 (en) | 2021-03-04 |
| KR20220051385A (ko) | 2022-04-26 |
| JP2022545279A (ja) | 2022-10-26 |
| EP4021421A1 (en) | 2022-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202122111A (zh) | 用於藥物溶解度控制之氣相塗層 | |
| Xu et al. | Stimuli-triggered multilayer films in response to temperature and ionic strength changes for controlled favipiravir drug release | |
| US20200338008A1 (en) | Coated Drug Compositions and Methods of Preparing the Same | |
| JP2014510066A (ja) | コーティングが施された固形医薬製剤 | |
| US20250255831A1 (en) | Vapor phase coating technology for pharmaceutical abuse deterrent formulations | |
| JP5214141B2 (ja) | 生理活性なブロック共重合体 | |
| Deng et al. | Orthogonal surface functionalization through bioactive vapor‐based polymer coatings | |
| Cagli et al. | Effect of side chain variation on surface and biological properties of poly (2-alkyl-2-oxazoline) multilayers | |
| Elkasabi et al. | Towards Multipotent Coatings: Chemical Vapor Deposition and Biofunctionalization of Carbonyl‐Substituted Copolymers | |
| CN101947320B (zh) | 介孔硅/聚合物复合型控释药物载体、其制备方法及应用 | |
| Gorbunova et al. | Novel biocidal polyampholytes with guanidinium and carboxy groups | |
| CN103191063B (zh) | 基于星型聚合物的层层自组装药物控释体系及制备方法 | |
| Osaki et al. | Controlled drug release through a plasma polymerized tetramethylcyclo-tetrasiloxane coating barrier | |
| Xu et al. | Environmentally Responsive Multilayer Films Based on Block Copolymer Micelles and Natural Peptides for Controlled Release of Favipiravir | |
| Wang et al. | A novel osmotic pump tablet using core of drug-resin complexes for time-controlled delivery system | |
| Yoo et al. | Ultrasonic spray coating of dextran-polyvinylamine composite for self-leveling, substrate-independent surface modification | |
| KR100498723B1 (ko) | 고체 기제의 표면을 체내 분해성폴리(1,4-디옥산-2-온)으로 코팅하는 방법 | |
| TWI482795B (zh) | 多官能基聚合物組成物及其合成方法 | |
| Selin | Chain Dynamics And Layering Within Polyelectrolyte Multilayer Films | |
| TWI276652B (en) | Method for forming shell crosslinked polymeric micelle | |
| CN115475255A (zh) | 一种酶响应型二氧化硅释纳米制剂、制备方法及应用 | |
| CN116407646A (zh) | 一种双载体双药温度响应型给药系统的制备方法及其应用 | |
| Menzel | Polymeric Ultrathin Films for Surface Modifications | |
| Madgulkar et al. | FORMULATION AND DEVELOPMENT OF SUSTAINED RELEASE PELLETS OF GLIPIZIDE |